- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Gall Bladder Disease in Belgium
Total 12122 results
-
GlaxoSmithKlineCompletedNeoplasms, Urinary BladderBelgium
-
University Hospital, GhentCompleted
-
University Hospital, GhentTakedaCompleted
-
University Hospital, GhentAstellas Pharma Inc; MedtronicCompleted
-
University Hospital, GhentTerminatedOveractive Bladder SyndromeBelgium
-
Universiteit AntwerpenUnknownOveractive Bladder, Non Obstructive Urinary RetentionBelgium
-
University Hospital, GhentKom Op Tegen KankerRecruitingMuscle-Invasive Bladder CarcinomaBelgium
-
KU LeuvenAgentschap voor Innovatie door Wetenschap en TechnologieCompletedBladder CancerBelgium
-
University Hospital, GhentCompletedSurgery | Bladder Cancer | Urologic CancerBelgium
-
University Hospital, GhentMedtronicCompletedUrinary Retention | Fecal Incontinence | Overactive Bladder Syndrome | Dysfunctional Voiding | Fowler SyndromeBelgium
-
University Hospital, GhentActive, not recruiting
-
Universiteit AntwerpenLeiden University Medical CenterUnknownOveractive Bladder | Non Obstructive Urinary RetentionBelgium
-
Universiteit AntwerpenLeiden University Medical CenterUnknownOveractive Bladder | Non Obstructive Urinary RetentionBelgium
-
Universiteit AntwerpenUnknown
-
Jessa HospitalCompletedBladder Cancer | Antibiotic-associated Diarrhea | Antibiotic Resistant Infection | Antibiotic Resistant Strain | Antibiotic Toxicity | Prostate Hyperplasia | UrosepsisBelgium
-
Amphora Medical, Inc.Terminated
-
National Multiple Sclerosis CenterTerminatedInterstitial Cystitis | Painful Bladder SyndromeBelgium
-
Amber Therapeutics LtdActive, not recruiting
-
University Hospital, GhentAlgemeen Ziekenhuis Maria Middelares; AZ Sint-Lucas Gent; AZ Jan Palfijn GentNot yet recruitingOveractive Bladder | Sacral Neuromodulation | Diversity | Onabotulinum Toxin A | Discrete Choice ExperimentBelgium
-
Axonics Modulation Technologies, Inc.CompletedOveractive BladderNetherlands, France, Belgium, United Kingdom
-
Jules Bordet InstituteMerck KGaA, Darmstadt, GermanyActive, not recruitingNon-metastatic Muscle Invasive Bladder CancerFrance, Belgium
-
PfizerCompletedNeurogenic Detrusor OveractivityBelgium
-
Universiteit AntwerpenRecruitingOveractive Bladder | Voiding Disorders | Pelvic Organ Prolapse | Stress Urinary Incontinence | Urge IncontinenceBelgium
-
Astellas Pharma Europe B.V.Veeda Clinical ResearchCompletedLower Urinary Tract Predominant Storage SymptomsBelgium
-
University of ZurichRecruitingNeurogenic Bladder DysfunctionBelgium, Brazil, Italy, Switzerland
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenRecruiting
-
Association Pour La Recherche des Thérapeutiques...Roche Pharma AGCompletedRecurrent Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the BladderFrance, Belgium
-
PfizerCompletedNeurogenic Detrusor OveractivityBelgium
-
European Organisation for Research and Treatment...TerminatedBladder CancerNetherlands, Belgium, Italy, Turkey, Slovakia
-
Astellas Pharma IncCompletedOveractive Bladder | Neurogenic Detrusor OveractivityBelgium, Canada, Denmark, Netherlands, Poland, Turkey, United Kingdom
-
Universiteit AntwerpenRecruitingOveractive Bladder | Lower Urinary Tract Symptoms | Enuresis | Voiding DisordersBelgium
-
AllerganCompletedOveractive BladderPoland, United Kingdom, Belgium, Russian Federation, Czech Republic, Germany, United States
-
MedtronicNeuroTerminatedUrinary Incontinence | Detrusor Overactivity | Neurogenic Overactive BladderBelgium, France, United Kingdom, Germany, Italy, Netherlands
-
VitadxFONDATION FORCE POUR L'INNOVATION ET LA RECHERCHE EN SANTERecruitingNon-muscle Invasive Bladder Cancer (NMIBC)France, Belgium, Spain
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedOveractive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor OveractivityBelgium, Denmark, Norway, Poland, Serbia
-
Astellas Pharma IncCompletedUrinary Bladder, OveractiveSweden, United Kingdom, Belgium, Denmark
-
AllerganCompletedOveractive Bladder | Urinary IncontinencePoland, Germany, United States, Canada, United Kingdom, Belgium
-
European Organisation for Research and Treatment...CompletedBladder CancerNetherlands, Belgium, United Kingdom, Italy, Portugal, Turkey
-
Acrotech Biopharma Inc.CompletedCarcinoma, Transitional Cell | Bladder Cancer | Bladder NeoplasmSpain, France, Belgium, United States, Argentina, Croatia
-
Slabbaert KoenUnknown
-
AllerganCompletedOveractive BladderUnited Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
-
Boehringer IngelheimCompletedBladder, NeurogenicBelgium, Spain, United States, India, South Africa, Philippines, Italy, Korea, Republic of, Russian Federation, Germany, Brazil, Mexico, Ukraine
-
Astellas Pharma Europe B.V.CompletedPediatric | Neurogenic Detrusor OveractivityUnited States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
-
AllerganCompletedOveractive Bladder | Urinary IncontinencePoland, United Kingdom, Belgium, Canada, Russian Federation, United States, Germany, Czechia
-
AllerganCompletedOveractive Bladder | Urinary IncontinencePoland, United Kingdom, Germany, Canada, Belgium, United States, Czechia
-
Boehringer IngelheimCompletedBladder, NeurogenicBelgium, Spain, United States, South Africa, Philippines, Italy, Korea, Republic of, Russian Federation, Germany, India, Brazil, Canada, Mexico, Ukraine
-
UNICANCERHoffmann-La RocheActive, not recruitingBladder CancerSpain, France, Belgium
-
ADC Therapeutics S.A.TerminatedBreast Cancer | Non Small Cell Lung Cancer | Bladder Cancer | GastroEsophageal CancerUnited States, Belgium
-
Astellas Pharma Global Development, Inc.RecruitingNeurogenic Detrusor OveractivityPhilippines, Turkey, Belgium, Denmark
-
European Organisation for Research and Treatment...CompletedBladder CancerNetherlands, Belgium, France, Austria, United Kingdom, Israel, Italy, Turkey, Greece, Portugal, Romania